September 2013 Blog Posts (37)

Combining Radiotherapy with a Novel Anti-cancer Drug APG101 may Offer new Treatment Option for Patients with Glioblastoma

Results from a clinical trial of a new treatment for glioblastoma (GBM) suggest that researchers may have found a new approach to treating this most aggressive of brain tumors, as well as a potential new biological marker than can predict the tumor’s response to treatment.

Presenting the research at ECC2013 - the European Cancer Congress [1] on Monday, September 30, 2013, Professor Dr. med. Wolfgang Wick, M.D., Chairman of the Neurooncology Program at the National Centre for…

Continue

Added by Editorial Team on September 30, 2013 at 10:00pm — No Comments

Report Shows Tackling Disparities in Cancer Care Worldwide Urgently Needed

While much progress has been made in the "war" against cancer, a new report, presented at the 2013 European Cancer Congress (ECCO 2013) being held in Amsterdam, The Netherlands, September 27 - October 1, 2013, shows that not every cancer patient has the opportunity to benefit from the progress made in prevention, diagnosis, treatment.

"The economics of cancer are daunting and the current model of financing is broken," noted Professor Peter Boyle, Ph.D, President of the…

Continue

Added by Editorial Team on September 30, 2013 at 9:30pm — No Comments

U.S. FDA Grants Accelerated Approval for Neoadjuvant use of Pertuzumab in Patients with High-risk, HER2-positive Early Stage Breast Cancer

Earlier today, the U.S. Food and Drug Administration (FDA) granted accelerated approval of a pertuzumab (Perjeta®, Genentech/Roche) regimen for neoadjuvant treatment in patients with high-risk, HER2-positive early stage breast cancer.

Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, approximately 235,000 people in the United States will be diagnosed with breast cancer, and 40,000 will die from the disease in 2013. In…

Continue

Added by Editorial Team on September 30, 2013 at 9:30pm — No Comments

Aspirin may Act on Blood Platelets to Improve Survival in Colon Cancer Patients

Although previous research has shown that taking low dose aspirin after being diagnosed with colon cancer improves patient outcome, the reasons why this happens remained, so far, unknown.

Now, new research shows that aspirin improves outcome in patients whose tumour cells express a specific protein known as Human Leukocyte Antigen class I (HLA class I), a cell-surface protein produced by a collection of genes involved in the functioning of the immune system. The…

Continue

Added by Editorial Team on September 30, 2013 at 8:30pm — No Comments

For the First Time Researchers have been able to Estimate the Daily Dose of Radiotherapy Wasted in Compensating for Tumor Growth Between Treatments

A new report, presented at the 2013 European Cancer Congress (ECC2013) shows that, for the first time, researchers have been able to estimated the daily dose of radiotherapy that could be wasted in compensating for cancer cell growth that occurs overnight and during weekends in patients with early breast cancer.

Professor John R. Yarnold, MD, FRCR, who is professor of clinical oncology at the Institute of Cancer Research and an honorary consultant at the Royal Marsden NHS…

Continue

Added by Editorial Team on September 30, 2013 at 6:30pm — No Comments

Cediranib Improves Survival in Women with Recurrent Ovarian Cancer

New study results presented at the 2013 European Cancer Congress (ECC2013), vein held in Amsterdam, The Netherlands, seem to suggest that women with ovarian cancer that has recurred after chemotherapy, have survived for longer after treatment with a biological therapy called cediranib (Proposed trade name: Recentin, AstraZeneca).[1]

Cediranib, also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases. This investigational…

Continue

Added by Editorial Team on September 30, 2013 at 10:30am — No Comments

ESMO Launches Unique Study on the Challenges of Female Medical Oncologists

Results from the ESMO Exploratory Survey on the Challenges of Female Oncologists, a project launched by ESMO President, Martine Piccart, MD, PhD, Professor of Oncology at the Université Libre de Bruxelles (ULB) and Director of Medicine at the Jules Bordet Institute, in Brussels, Belgium, were presented during the ESMO Women for Oncology (W4O) Forum at the 2013 European Cancer Congress ECC2013 Congress, being held in Amsterdam, The Netherlands and show that the relationship with patients…

Continue

Added by Editorial Team on September 30, 2013 at 9:00am — No Comments

Organized Prostate Cancer Screening with PSA-test does More Harm than Good

Despite a lack of evidence showing that it reduces cancer deaths, prostate cancer screening using the prostate-specific antigen or PSA-test is widely used in France. Now, according to research presented by Professor Mathieu Boniol, MD, at the 2013 European Cancer Congress (ECC2013), being held in Amsterdam, The Netherlands, September 27 - October 1, 2013, researchers have shown that men experience more harm than good from routine PSA screening.

Boniol, Research Director at…

Continue

Added by Editorial Team on September 29, 2013 at 11:30pm — No Comments

Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) Shows Promising Results In Lung Cancer

Data presented at the 2013 European Cancer Congress (ECC2013) being held in Amsterdam, The Netherlands from September 27 to October 1, 2013 shows results from a trial of an antibody that helps the immune system to recognise and attack cancer cells, showing particularly encouraging responses in patients who are currently smoking or who are former smokers. The experimental drug, MPDL3280A (RG7446, also known as anti-PDL1), was generally well tolerated and yielded often rapid, durable…

Continue

Added by Editorial Team on September 29, 2013 at 9:00pm — No Comments

Radiation Therapy to the Lymph Node Improves Survival in Patients with Early Breast Cancer

Patients diagnosed with early breast cancer may benefit from radiation therapy to the lymph nodes located behind the breast bone and above the collar bone. New finding show that this approach improves overall survival without increasing unwanted side effects. The study results, presented at the 2013 European Cancer Congress (ECC2013) being held in Amsterdam, The Netherlands, September 27 - October 1, 2013, also ends the uncertainty about whether the beneficial effect of radiation therapy…

Continue

Added by Editorial Team on September 28, 2013 at 9:00pm — No Comments

'Irrefutable’ Evidence Shows that Colorectal Cancer Screening Works

Screening for colorectal cancer (CRC) in European countries is highly effective in reducing mortality from the disease. A number of researchers in population based studies argue therefore, that some resources, currently being devoted to breast and prostate screening programs where the evidence of effectiveness is much less clear-cut, should be reallocated to the early detection of CRC. Data supporting this argument were presented at the 2013 European Cancer Congress (ECC2013), being held…

Continue

Added by Editorial Team on September 28, 2013 at 8:00pm — No Comments

Patients with Advanced HER2-Positive Breast Cancer Live Longer Without Their Disease Worsening in New Phase III Study with Ado-trastuzumab Emtansine

Ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche) significantly extended progression-free survival [PFS] in patients with advanced HER2-positive metastatic and unresectable locally advanced/recurrent breast cancer, thus extending the times people lived without their disease worsening.

This is one of the conclusions from an open-label Phase III study called TH3RESA which evaluated the efficacy and safety of ado-trastuzumab emtansine or T-DM1 in comparison with treatment of…

Continue

Added by Editorial Team on September 28, 2013 at 8:00pm — No Comments

High Risk of Disease Progression and Death in Young Patients with Metastatic Colorectal Cancer

Younger patients with metastasized colorectal cancer represent a high-risk group that is less likely to respond to anti-cancer treatments. According to new research presented at the 2013 European Cancer Congress (ECC2013), being held in Amsterdam, The Netherlands, from September 27 until October 1, 2013, their disease is more likely to progress and they are at greater risk of death than other age groups. [1]

An analysis of 20,034 patients in 24 phase III clinical trials for…

Continue

Added by Editorial Team on September 28, 2013 at 7:00pm — No Comments

Ipilimumab Offers Survival Benefit for Patients with Advanced Melanoma

Patients with advanced melanoma, who have been treated with the monoclonal antibody (mAb) ipilimumab (Yervoy®, Bristol-Myers Squibb Company) can survive for up to ten years. This is a conclusion based on the results of the largest analysis of overall survival for these patients presented at the 2013 European Cancer Congress (ECC2013)[1].…

Continue

Added by Editorial Team on September 28, 2013 at 5:00pm — No Comments

Cancer Survival Strongly Associated with Healthcare Spending

Research presented at the 2013 European Cancer Congress (ECC2013) being held in Amsterdam, The Netherlands from September 27 to October 1, 2013 and published simultaneously in the leading cancer journal Annals of Oncology, shows that increased health expenditure is associated with better cancer outcome.[1]

The researchers looked at the health expenditure of the 27 member states of the European Union (EU) and noted that higher wealth and higher health expenditure are strongly…

Continue

Added by Editorial Team on September 28, 2013 at 3:00pm — No Comments

Survival in Head and Neck Cancer Patients Improved by Hyperfractionated Radiotherapy

The use of an intensified form of radiotherapy in patients with locally advanced head and neck cancers can improve overall survival rates compared with standard radiation therapy. This is the conclusion drawn from results from a large study presented at the 2013 European Cancer Congress (ECC2013)[1].…

Continue

Added by Editorial Team on September 28, 2013 at 3:00pm — No Comments

Study Confirms Everolimus Slows Disease Progression in Advanced Papillary Kidney Cancer

The first Phase II study to investigate the use of the anti-cancer drug everolimus (Afinitor®; Novartis)[1], used for the initial treatment of patients with advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease. The study results were presented at the 2013 European Cancer Congress (ECC2013), being held in Amsterdam, The Netherlands, September 27 - October 1,…

Continue

Added by Editorial Team on September 28, 2013 at 12:00pm — No Comments

Patients with Diabetes have an Increased Risk of Developing and Dying from Breast and Colon Cancer

Diabetes and cancer are common diseases with tremendous impact on health and healthcare worldwide expenditure. A growing number of epidemiological and clinical studies find evidence suggesting that diabetes is directly linked to an increased risk of developing certain types of cancer.[1] Now, researchers in The Netherlands have performed a unique meta-analysis that excludes all other causes of death and found that diabetic patients not only have an increased risk of developing breast and…

Continue

Added by Editorial Team on September 28, 2013 at 10:30am — No Comments

Reduced Side Effects for Pediatric Head and Neck Cancer Patients Treated with Proton Therapy

A new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania shows that precise targeting and limited dosing of radiation via proton therapy proves to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients.

Standard (x-ray) radiation treatment and proton therapy are significantly different. Sufficient…

Continue

Added by Editorial Team on September 24, 2013 at 3:30pm — No Comments

Targeted Radiation is Safe and Effective for Elderly Pancreatic Cancer Therapy

A highly targeted cancer radiation therapy called stereotactic body radiotherapy or SBRT may offer a safe and effective treatment option for elderly pancreatic cancer patients unable to undergo surgery or combined chemotherapy and radiation therapy, according to researchers at Henry Ford Hospital in Detroit.

A stereotactic radiation treatment is a method of giving radiation that can be highly targeted to the tumor,…

Continue

Added by Editorial Team on September 24, 2013 at 8:30am — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+